Intranasal Delivery of Neuropeptide-Loaded Nanoparticles and Their Application to Nervous System Therapeutics

  • Michael J. Kubek
  • Abraham J. Domb
  • Daniel J. Kubek
  • Michael C. Veronesi
Part of the Advances in Delivery Science and Technology book series (ADST)


The neuropeptides represent a rapidly expanding class of promising new CNS drugs. Unfortunately, the delivery of neuropeptides to the brain has been a major obstacle in their therapeutic development. Rapid metabolism in all tissue compartments and a lack of blood–brain barrier (BBB) penetration are two daunting issues related to neuropeptide bioavailability. Interestingly, within the nasal cavity the olfactory epithelium contains olfactory neurons that are the only nerves in direct contact with the external environment. This unique neuroanatomical relationship presents a means to limit metabolism and bypass the BBB to enhance access to olfactory neuronal transport mechanisms to target the CNS. However, several transolfactory barriers exist. Airborne particles entering the nasal cavity are destined for three epithelial regions: vestibular, respiratory, and olfactory. The olfactory region is an important site for access to the brain. Three major barriers to neuropeptide bioavailability exist in this region: the presence of tight junctions between sensory neurons and supporting cells, preventing epithelial transport to the submucous space; a mucous layer containing protective proteolytic/hydrolytic enzymes that impart an enzymatic barrier; and a mucous layer clearance that influences time-dependent neuropeptide absorption (uptake). Following olfactory neuroepithelium uptake, neuropeptides are susceptible to further degradation during transneuronal transport as they are carried to primary olfactory structures. Next, sufficient sustained neuropeptide release is necessary for a pharmacological effect. The development of newer surface-eroding biodegradable nanoparticle (NP) carriers could provide a means of mitigating these impediments to better exploit this nose-to-brain pathway. In order to evaluate this delivery approach, we utilized a rat model of temporal lobe epilepsy (kindling) to show (1) that copolymer microdisks loaded with the neuropeptide thyrotropin-releasing hormone (TRH) implanted in the seizure focus could attenuate kindling development (seizureogenesis); (2) intranasal administration of an unprotected TRH analog could acutely suppress generalized seizures in a concentration-dependent manner; and (3) intranasal administration of TRH-loaded nanoparticles (TRH-NPs) could release sufficient TRH at the seizure focus to impede kindling development (seizureogenesis). Additionally, we utilized intranasal delivery of fluorescent dye-loaded NPs in rats and application of dye-loaded or dye-attached NPs to cortical neurons in culture to demonstrate NP uptake and distribution over time in vivo and in vitro, respectively. Also, an NP immunostaining method was developed to directly visualize the tissue density and distribution of TRH-NPs. Taken together, our preclinical data provides further proof of concept for intranasal administration of neuropeptide-loaded NPs as a feasible means to noninvasively deliver these compounds safely and repeatedly as a novel delivery platform for neuropeptide CNS therapeutics.


Nasal Cavity Olfactory Epithelium Mucous Layer Intranasal Administration Seizure Focus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Doty RL (1995) Introduction and historical perspective. Marcel Dekker, New York, NY, pp 1–32Google Scholar
  2. 2.
    Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, Craft S (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13:323–331PubMedCentralPubMedGoogle Scholar
  3. 3.
    Pirard C, Loumaye E (2005) GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 20:1798–1804CrossRefPubMedGoogle Scholar
  4. 4.
    Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514–516CrossRefPubMedGoogle Scholar
  5. 5.
    Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH, Toth C (2008) Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131:3311–3334CrossRefPubMedGoogle Scholar
  6. 6.
    Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH (2008) Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152:785–797CrossRefPubMedGoogle Scholar
  7. 7.
    Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stage. J Mol Neurosci 31:165–170PubMedGoogle Scholar
  8. 8.
    Baker H (1995) Transport phenomena within the olfactory system. Marcel Dekker, New York, NY, pp 173–190Google Scholar
  9. 9.
    Mathison S, Nagilla R, Kompella UB (1998) Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 5:415–441CrossRefPubMedGoogle Scholar
  10. 10.
    Kubek MJ, Ringel I, Domb AJ (2001) Issues related to intranasal delivery of neuropeptides to temporal lobe targets. Springer, New York, NY, pp 323–350Google Scholar
  11. 11.
    Lockman PR, Mumper RJ, Khan MA, Allen DD (2002) Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev Ind Pharm 28:1–13CrossRefPubMedGoogle Scholar
  12. 12.
    Gozes I, Brenneman DE, Geppetti P, Kastin AJ, Mains RE, Moody TW, Seroogy K, Spier AD, Zimmermann M (2001) Neuropeptides: brain messengers of many faces. Trends Neurosci 24:687–690CrossRefPubMedGoogle Scholar
  13. 13.
    Illum L (2004) Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3–17CrossRefPubMedGoogle Scholar
  14. 14.
    Agarwal V, Mishra B (1999) Recent trends in drug delivery systems: intranasal drug delivery. Indian J Exp Biol 37:6–16PubMedGoogle Scholar
  15. 15.
    Egleton RD, Davis TP (2005) Development of neuropeptide drugs that cross the blood–brain barrier. NeuroRx 2:44–53PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Mistry A, Stolnik S, Illum L (2009) Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–157CrossRefPubMedGoogle Scholar
  17. 17.
    Mygind N, Anggard A (1984) Anatomy and physiology of the nose-pathophysiologic alterations in allergic rhinitis. Clin Rev Allergy 2:173–188PubMedGoogle Scholar
  18. 18.
    Chien YW, Chang S (1987) Intranasal drug delivery for systemic medication. Crit Rev Ther Drug Carrier Syst 4:67–194PubMedGoogle Scholar
  19. 19.
    Khanvilker K, Donovan MD, Flanagan DR (2001) Drug transfer through mucus. Adv Drug Deliv Rev 28:173–193CrossRefGoogle Scholar
  20. 20.
    Wermeling DP, Miller JL, Rudy AC (2004) Systematic intranasal drug delivery: concept and applications. Drug Deliv Technol 2:22–30Google Scholar
  21. 21.
    Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435:673–676CrossRefPubMedGoogle Scholar
  22. 22.
    Lewis J, Dahl AR (1995) Olfactory mucosa: composition, enzymatic localization, and metabolism. Marcel Dekker, New York, NY, pp 33–52Google Scholar
  23. 23.
    Morrison EE, Moran DT (1995) Anatomy and ultrastructure of the human olfactory neuroepithelium. Marcel Dekker, New York, NY, pp 75–101Google Scholar
  24. 24.
    Kratskin IL (1995) Functional anatomy, central connections, and neurochemistry of the mammalian olfactory bulb. Marcel Dekker, New York, NY, pp 103–126Google Scholar
  25. 25.
    Barnea G, O’Donnell S, Mancia F, Sun X, Nemes A, Mendelsohn M, Axel R (2004) Odorant receptors on axon termini in the brain. Science 304:1468CrossRefPubMedGoogle Scholar
  26. 26.
    Watelet J-B, Katotomichelakis M, Eloy P, Danielidis V (2009) The physiological basics of the olfactory neuro-epithelium. B-ENT 5:11–19PubMedGoogle Scholar
  27. 27.
    Thorne RG, Emory CR, Ala TA, Frey WH (1995) Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692:278–282CrossRefPubMedGoogle Scholar
  28. 28.
    Ochs S, Brimijoin WS (1993) Axonal transport, 3rd edn. WB Saunders, Philadelphia, PA, pp 331–360Google Scholar
  29. 29.
    Shipley MT (1985) Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull 15:129–142CrossRefPubMedGoogle Scholar
  30. 30.
    Heuer H, Schafer MKH, Bauer K (1998) The thyrotropin-releasing hormone-degrading ectoenzyme: the third element of the thyrotropin-releasing hormone-signaling system. Thyroid 8:915–920CrossRefPubMedGoogle Scholar
  31. 31.
    Griffiths EC, Kelly JA, Ashcroft A, Ward DJ, Robson B (1989) Part V. TRH metabolism. Comparative metabolism and conformation of TRH and its analogues. Ann NY Acad Sci 553:217–231CrossRefPubMedGoogle Scholar
  32. 32.
    Rechsteiner M, Hill CP (2005) Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 15:27–33CrossRefPubMedGoogle Scholar
  33. 33.
    Illum L (2000) Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1–18CrossRefPubMedGoogle Scholar
  34. 34.
    Kubek MJ, Domb AJ, Veronesi MC (2009) Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 6:359–371CrossRefPubMedGoogle Scholar
  35. 35.
    Kanayama Y, Enomoto S, Irie T, Amano R (2005) Axonal transport of rubidium and thallium in the olfactory nerve of mice. Nucl Med Biol 32:505–512CrossRefPubMedGoogle Scholar
  36. 36.
    Wermeling DP (2009) Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 6:352–358CrossRefPubMedGoogle Scholar
  37. 37.
    Sarkar MA (1992) Drug metabolism in the nasal mucosa. Pharm Res 9:1–9CrossRefPubMedGoogle Scholar
  38. 38.
    Tsuji A (2005) Small molecular drug transfer across the blood–brain barrier via carrier-mediated transport systems. NeuroRx 2:54–62PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Pardridge WM (2005) The blood–brain barrier: bottleneck in brain drug development. NeuroRx 2:3–14PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Cross R, Scholey J (1999) Kinesin: the tail unfolds [news; comment]. Nat Cell Biol 1:E119–E121CrossRefPubMedGoogle Scholar
  41. 41.
    Cross DJ, Minoshima S, Anzai Y, Flexman JA, Keogh BP, Kim Y, Maravilla KR (2004) Statistical mapping of functional olfactory connections of the rat brain in vivo. Neuroimage 23:1326–1335CrossRefPubMedGoogle Scholar
  42. 42.
    Takeda A, Kodama Y, Ishiwatari S, Okada S (1998) Manganese transport in the neural circuit of rat CNS. Brain Res Bull 45:149–152CrossRefPubMedGoogle Scholar
  43. 43.
    O’Cuinn G, O’Connor B, Elmore M (1990) Degradation of thyrotropin-releasing hormone and luteinising hormone-releasing hormone by enzymes of brain tissue. J Neurochem 54:1–13CrossRefPubMedGoogle Scholar
  44. 44.
    Kristensson K, Olsson Y (1971) Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol 19:145–154CrossRefPubMedGoogle Scholar
  45. 45.
    Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia PJ, L’Herrou TA, Leverich GS, Post RM (1997) Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 54:214–222CrossRefPubMedGoogle Scholar
  46. 46.
    Callahan AM, Frye MA, Marangell LB, George MS, Ketter TA, L’Herrou T, Post RM (1997) Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. Biol Psychiatry 41:264–272CrossRefPubMedGoogle Scholar
  47. 47.
    Szuba MP, Amsterdam JD, Fernando AT III, Gary KA, Whybrow PC, Winokur A (2005) Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol 25:325–330CrossRefPubMedGoogle Scholar
  48. 48.
    Nillni EA, Sevarino KA (1999) The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev 20:599–648PubMedGoogle Scholar
  49. 49.
    Gary KA, Sevarino KA, Yarbrough GG, Prange AJ Jr, Winokur A (2003) The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther 305:410–416CrossRefPubMedGoogle Scholar
  50. 50.
    Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr (2008) Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69:946–958PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Kubek MJ, Garg BP (2002) Thyrotropin-releasing hormone (TRH) in the treatment of intractable epilepsy. Pediatr Neurol 26:9–17CrossRefPubMedGoogle Scholar
  52. 52.
    Kubek MJ, Liang D, Byrd KE, Domb AJ (1998) Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res 809:189–197CrossRefPubMedGoogle Scholar
  53. 53.
    Veronesi MC, Kubek DJ, Kubek MJ (2007) Intranasal delivery of a thyrotropin-releasing hormone analog attenuates seizures in the amygdala-kindled rat. Epilepsia 48:2280–2286PubMedGoogle Scholar
  54. 54.
    Veronesi MC, Aldouby Y, Domb AJ, Kubek MJ (2009) Thyrotropin-releasing hormone d, l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo. Brain Res 1303:151–160CrossRefPubMedGoogle Scholar
  55. 55.
    Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, Cheng JX, Kohane DS, Yeo Y (2009) Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm 6:190–201PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Kubek MJ, Hill TG (1987) Methods of Thyrotropin-releasing hormone measurement. In: Hingtgen JN, Hellhammer DH, Huppmann G (eds) Advanced Methods In Psychology. CJ Hogrefe, Inc. Toronto, pp 261–279Google Scholar
  57. 57.
    Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey WH II (1998) Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimer’s Dis 1:35–45Google Scholar
  58. 58.
    Kubek MJ, Yard M, Lahiri DK, Domb AJ (2007) Characterization of novel intranasal sustained-release nanoparticles for delivery of neuropeptides to the brain. American Scientific Publishers, New York, NY, pp 73–84Google Scholar

Copyright information

© Controlled Release Society 2014

Authors and Affiliations

  • Michael J. Kubek
    • 1
    • 2
    • 3
  • Abraham J. Domb
    • 4
  • Daniel J. Kubek
    • 1
    • 5
  • Michael C. Veronesi
    • 6
  1. 1.Department of Anatomy and Cell BiologyIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of PsychiatryIndiana University School of MedicineIndianapolisUSA
  3. 3.Program in Medical NeuroscienceIndiana University School of MedicineIndianapolisUSA
  4. 4.Faculty of Medicine, Institute for Drug Research, School of PharmacyThe Hebrew UniversityJerusalemIsrael
  5. 5.School of Dentistry, University of LouisvilleLouisvilleUSA
  6. 6.Department of RadiologyUniversity of Chicago School of MedicineChicagoUSA

Personalised recommendations